drugset / Trial / NCT00383396

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

NCT00383396

Phase 4 Completed Innovative Medical
RandomizedSingle-groupOpen-label

Summary

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.05 % Topical

Indications